Jump to content

Shigatoxigenic and verotoxigenic Escherichia coli

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by OAbot (talk | contribs) at 11:50, 12 April 2020 (Open access bot: doi added to citation with #oabot.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

"Enterohemorrhagic", meaning "causing bloody diarrhea", redirects here. For bloody diarrhea in general, see Dysentery.
Shigatoxigenic and verotoxigenic E. coli
SpecialtyInfectious disease

Shigatoxigenic Escherichia coli (STEC) and verotoxigenic E. coli (VTEC) are strains of the bacterium Escherichia coli that produce either Shiga toxin or Shiga-like toxin (verotoxin). Only a minority of the strains cause illness in humans.[1][failed verification] The ones that do are collectively known as enterohemorrhagic E. coli (EHEC) and are major causes of foodborne illness. When infecting humans, they often cause gastroenteritis, enterocolitis, and bloody diarrhea (hence the name "enterohemorrhagic") and sometimes cause a severe complication called hemolytic-uremic syndrome (HUS).[2] The group and its subgroups are known by various names. They are distinguished from other strains of intestinal pathogenic E. coli including enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli (EAEC), and diffusely adherent E. coli (DAEC).[3]

Background

The best known of these strains is O157:H7, but non-O157 strains cause an estimated 36,000[citation needed] illnesses, 1,000 hospitalizations and 30 deaths in the United States yearly.[4] Food safety specialists recognize "Big Six" strains: O26; O45; O103; O111; O121; and O145.[4] A 2011 outbreak in Germany was caused by another STEC, O104:H4. This strain has both enteroaggregative and enterohemorrhagic properties. Both the O145 and O104 strains can cause hemolytic-uremic syndrome (HUS); the former strain shown to account for 2% to 51% of known HUS cases; an estimated 56% of such cases are caused by O145 and 14% by other EHEC strains.

EHECs that induce bloody diarrhea lead to HUS in 10% of cases. The clinical manifestations of postdiarrheal HUS include acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia. The verocytotoxin (shiga-like toxin) can directly damage renal and endothelial cells. Thrombocytopenia occurs as platelets are consumed by clotting. Hemolytic anemia results from intravascular fibrin deposition, increased fragility of red blood cells, and fragmentation.[3]

Antibiotics are of questionable value and have not shown to be of clear clinical benefit. Antibiotics that interfere with DNA synthesis, such as fluoroquinolones, have been shown to induce the Stx-bearing bacteriophage and cause increased production of toxins.[5] Attempts to block toxin production with antibacterials which target the ribosomal protein synthesis are conceptually more attractive. Plasma exchange offers a controversial but possibly helpful treatment. The use of antimotility agents (medications that suppress diarrhea by slowing bowel transit) in children under 10 years of age or in elderly patients should be avoided, as they increase the risk of HUS with EHEC infections.[3]

The clinical presentation ranges from a mild and uncomplicated diarrhea to a hemorrhagic colitis with severe abdominal pain. Serotype O157:H7 may trigger an infectious dose with 100 bacterial cells or fewer; other strain such as 104:H4 has also caused an outbreak in Germany 2011. Infections are most common in warmer months and in children under five years of age and are usually acquired from uncooked beef and unpasteurized milk and juice. Initially a non-bloody diarrhea develops in patients after the bacterium attaches to the epithelium or the terminal ileum, cecum, and colon. The subsequent production of toxins mediates the bloody diarrhea. In children, a complication can be hemolytic uremic syndrome which then uses cytotoxins to attack the cells in the gut, so that bacteria can leak out into the blood and cause endothelial injury in locations such as the kidney by binding to globotriaosylceramide (Gb3).

Names

Names of the group and its subgroups include the following.[6] There is some polysemy involved. Invariable synonymity is indicated by having the same color. Beyond that there is also some wider but variable synonymity. The first two (purple) in their narrowest sense are generally treated as hypernyms of the others (red and blue), although in less precise usage the red and blue have often been treated as synonyms of the purple. At least one reference holds "EHEC" to be mutually exclusive of "VTEC" and "STEC",[2] but this does not match common usage, as many more publications lump all of the latter in with the former. If one defines Shiga toxin as the exact toxin of Shigella dysenteriae, down to every last amino acid residue, then one can view all of the Escherichia coli strains that produce any similar toxin as VTEC, with all of their toxins being SLT, not ST; but the equally reasonable view of STEC as producing "the same" toxin as Shigella dysenteriae (because the difference is negligible for most purposes) contradistinguishes STEC from VTEC. Practically, the choice of words and categories is not as important as the understanding of clinical relevance. As microbiology advances, the historical variation in nomenclature (which arose because of gradually advancing science in multiple places) is increasingly giving way to recognizing all of these molecules as "versions of the same toxin" rather than "different toxins".[7]: 2–3 

Name Short form
enterohemorrhagic E. coli EHEC
hemolytic uremic syndrome–associated enterohemorrhagic E. coli HUSEC
shiga toxin–producing E. coli STEC
shigatoxigenic E. coli STEC
shiga-like toxin–producing E. coli SLTEC
verotoxin-producing E. coli VTEC
verotoxigenic E. coli VTEC
verocytotoxin-producing E. coli VTEC
verocytotoxigenic E. coli VTEC

Infectivity and virulence

The infectivity or the virulence of an EHEC strain depends on several factors, including the presence of fucose in the medium, the sensing of this sugar and the activation of EHEC pathogenicity island.

Scheme of the signalling cascade in EHEC where we can observe the effect of the sensing of some signalling molecules in the virulence of eneterohaemorragic E. coli

Regulation of the pathogenicity island

EHEC becomes pathogenic through the expression of the locus of enterocyte effacement (LEE) encoded on its pathogenicity island. However, when EHEC is not in a host this expression is a waste of energy and resources, so it is only activated if some molecules are sensed in the environment.

When QseC or QseE bind with one of their interacting signalling molecule, they autophosphorylate and transfer its phosphate to the response regulator. QseC senses adrenaline, noradrenaline, and an Endonuclease I-SceIII, encoded by a mobile group I intron within the mitochondrial COX1 gene (AI3); whereas QseE senses adrenaline, noradrenaline, SO4 and PO4. These signals are a clear indication to the bacteria that they are no longer free in the environment, but in the gut.

As a result, QseC phosphorylates QseB (which activates flagella), KpdE (which activates the LEE) and QseF. QseE phosphorylates QseF. The products QseBC and QseEF repress the expression of FusK and FusR. FusK and FusR are the two components of a system to repress the transcription of the LEE genes. FusK is a sensor kinase which is able to sense many sugars among which fucose. When fucose is present in the medium FusK phosphorylates FusR which represses LEE expression.

Thus when EHEC enters the gut there is a competition between the signals coming from QseC and QseF, and the signal coming from FusK. The first two would like to activate virulence, but Fusk stops it because the mucous layer, which is a source of fucose, isolates enterocytes from bacteria making the synthesis of the virulence factors useless. However, when fucose concentration decreases because bacterial cells find an unprotected area of the epithelium, then the expression of LEE genes will not be repressed by FusR, and KpdE will strongly activate them. In summary, the combined effect of the QseC/QseF and FusKR provide a fine-tuning system of LEE expression which saves energy and allow the mechanisms of virulence to be expressed only when the chances of success are higher.

FusKR complex

This complex, formed by two components (FusK and FusR) has the function in EHEC to detect the presence of fucose in the environment and regulate the activation of LEE genes. -FusK: is encoded by the z0462 gene. This gene is an histidine kinase sensor. It detects fucose and then phosphorylates the Z0463 gene activating it. -FusR: is encoded by the z0463 gene. This gene is a repressor of LEE genes. When z0462 gene detects fucose, phosphorylates and activates the Z0463 gene, which will repress the expression of 'le r', the regulator of the LEE genes. If z0463 gene is not active, the expression of the gene ler would not be repressed. The expression of 'ler' activates the remaining genes in the pathogenicity island inducing virulence. -At the same time, the system FusKR inhibits the Z0461 gene, a fucose transporter.

Inactivation of LEE genes ( ↑ [fucose] )

Fucose increases the activation of the FusKR system, which inhibits the z0461 gene, which controls the metabolism of fucose. This is a mechanisms that is useful to avoid the competition for fucose with other strains of E. coli which are usually more efficient at using fucose as a carbon source. High concentrations of fucose in the medium also increases the repression of the LEE genes.

Activation of LEE genes ( ↓ [fucose] )

With low levels of fucose in the environment, the FusKR system is inactive, and this means that z0461 gene is transcribed, thus increasing the metabolism of fucose. Furthermore, a low concentration of fucose is an indication of unprotected epithelium, thus the repression of ler genes will disappear and the expression of the LEE genes will allow to attack the adjacent cells.

See also

References

  1. ^ Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB (2013). "Recent advances in understanding enteric pathogenic Escherichia coli". Clinical Microbiology Reviews. 26 (4): 822–80. doi:10.1128/CMR.00022-13. PMC 3811233. PMID 24092857.
  2. ^ a b Mainil, J (1999), "Shiga/verocytotoxins and Shiga/verotoxigenic Escherichia coli in animals", Vet Res, 30 (2–3): 235–57, PMID 10367357.
  3. ^ a b c Bae, Woo Kyun; Lee, Youn Kyoung; Cho, Min Seok; Ma, Seong Kwon; Kim, Soo Wan; Kim, Nam Ho; Choi, Ki Chul (2006-06-30). "A Case of Hemolytic Uremic Syndrome Caused by Escherichia coli O104:H4". Yonsei Med J. 47 (3): 437–439. doi:10.3349/ymj.2006.47.3.437. PMC 2688167. PMID 16807997. Two sentences were taken from this source verbatim.
  4. ^ a b Mallove, Zach (26 April 2010). "Lawyer Battles FSIS on Non-O157 E. coli". Food Safety News. Retrieved 2 June 2011.
  5. ^ Zhang, X; McDaniel, AD; Wolf, LE; Keusch, GT; Waldor, MK; Acheson, DW (2000). "Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice". The Journal of Infectious Diseases. 181 (2): 664–70. doi:10.1086/315239. PMID 10669353.
  6. ^ Karch, Helge; Tarr, Phillip I.; Bielaszewska, Martina (2005). "Enterohaemorrhagic Escherichia coli in human medicine". International Journal of Medical Microbiology. 295 (6–7): 405–18. doi:10.1016/j.ijmm.2005.06.009. PMID 16238016.
  7. ^ Silva, Christopher J.; Brandon, David L.; Skinner, Craig B.; He, Xiaohua; et al. (2017), "Chapter 3: Structure of Shiga toxins and other AB5 toxins", Shiga toxins: A Review of Structure, Mechanism, and Detection, Springer, ISBN 978-3319505800.

Further reading

  1. Bardiau, M.; M. Szalo; J.G. Mainil (2010). "Initial adherence of EPEC, EHEC and VTEC to host cells". Vet Res. 41 (5): 57. doi:10.1051/vetres/2010029. PMC 2881418. PMID 20423697. {{cite journal}}: Unknown parameter |lastauthoramp= ignored (|name-list-style= suggested) (help)
  2. Wong, A.R. (2011). "Enteropathogenic and enterohaemorrhagic Escherichia coli: even more subversive elements". Mol Microbiol. 80 (6): 1420–38. doi:10.1111/j.1365-2958.2011.07661.x. PMID 21488979. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
  3. Tatsuno, I. (2007). "[Adherence of enterohemorrhagic Escherichia coli O157:H7 to human epithelial cells]". Nihon Saikingaku Zasshi. 62 (2): 247–53. PMID 17575791.
  4. Kaper, J.B.; J.P. Nataro; H.L. Mobley (2004). "Pathogenic Escherichia coli". Nat Rev Microbiol. 2 (2): 123–40. doi:10.1038/nrmicro818. PMID 15040260. {{cite journal}}: Unknown parameter |lastauthoramp= ignored (|name-list-style= suggested) (help)
  5. Garcia, A.; J.G. Fox; T.E. Besser (2010). "Zoonotic enterohemorrhagic Escherichia coli: A One Health perspective". ILAR J. 51 (3): 221–32. doi:10.1093/ilar.51.3.221. PMID 21131723. {{cite journal}}: Unknown parameter |lastauthoramp= ignored (|name-list-style= suggested) (help)
  6. Shimizu, T. (2010). "[Expression and extracellular release of Shiga toxin in enterohemorrahgic Escherichia coli]". Nihon Saikingaku Zasshi. 65 (2–4): 297–308. doi:10.3412/jsb.65.297. PMID 20505269.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Shigatoxigenic_and_verotoxigenic_Escherichia_coli&oldid=950503409"